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The treatment and care of individuals who have a Difference of Sex Development (DSD) 52 
have been revised over the past two decades and new guidelines have been published. In 53 
order to study the impact of treatments and new forms of management in these rare and 54 
heterogeneous conditions, standardized assessment procedures across centres are needed. 55 
Diagnostic work-up and detailed genital phenotyping are crucial at first assessment. DSDs 56 
may affect general health, have associated features or lead to comorbidities which may only 57 
be observed through lifelong follow-up. The impact of medical treatments and surgical (non-) 58 
interventions warrants special attention in the context of critical review of current and future 59 
care. It is equally important to explore gender development early and refer to specialized 60 
services if needed. DSDs and the medical, psychological, cultural and familial ways of 61 
dealing with it may affect self-perception, self-esteem, and psychosexual function. Therefore, 62 
psychosocial support has become one of the cornerstones in the multidisciplinary 63 
management of DSD, but its impact remains to be assessed.   64 
Careful clinical evaluation and pooled data reporting in a global DSD registry will allow linking 65 
genetic, metabolomic, phenotypic and psychological data. For this purpose, our group of 66 
clinical experts and patient and parent representatives designed a template for structured 67 
longitudinal follow-up. In this paper, we explain the rationale behind the selection of the 68 
dataset. This tool provides guidance to professionals caring for individuals with a DSD and 69 
their families. At the same time, it collects the data needed for answering unsolved questions 70 
of patients, clinicians, and researchers. Ultimately, outcomes for defined subgroups of rare 71 
DSD conditions should be studied through large collaborative endeavours using a common 72 
protocol.  73 
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1. Introduction 74 
The term Differences (Disorders) of Sex Development (DSD) refers to a heterogeneous 75 
group of conditions that affect the urogenital tract and result in atypical sex development. The 76 
prevalence of the individual conditions is mostly very low and only a small fraction of all 77 
conditions characterised by variations in sex characteristics pose major clinical challenges 78 
and/or require multidisciplinary care 1. Recent outcome studies suggest that having a DSD 79 
may impact an individuals’ health status and psychological well-being in every stage of life 2-80 
4, though physical or psychological co-morbidities have been rarely studied in detail, 81 
especially in adults. Influencing factors include the rarity of the respective conditions, 82 
individual drawbacks to participate in medical studies and the dispersion of affected 83 
individuals over decentralised health care structures, with frequent loss of patients for follow-84 
up. In addition, the quality of care for individuals with a DSD varies considerably across 85 
Europe, between centres and within diagnostic groups. Patient satisfaction with care is 86 
lowest among individuals with the rarest conditions 5.  87 
The development of a concrete and evidence-based protocol for structured review and 88 
clinical data collection in children and adults who have a DSD, at various age intervals, may 89 
be pivotal in addressing these difficulties 6 (Figure 1). It minimizes bias in clinical 90 
assessments and can provide guidance to clinicians who do not regularly see these patients. 91 
In fact, there is a need to support health care professionals in assessing a small amount of 92 
data regularly as part of a holistic routine clinical care. Equally important, it enables 93 
exchange of data among clinical centres and in research networks such as the international 94 
DSD Registry I-DSD (www. https://i-dsd.org), allowing large-scale multicentre studies. For 95 
patients, it can increase understanding of their condition, provide clarity about one’s future 96 
medical needs, enhance compliance and facilitate discussions with caregivers 7. From a 97 
healthcare point of view, adherence to an evidence-based assessment protocol can serve as 98 
a quality indicator and benchmarking tool 8.      99 
Several aspects of DSD management are surrounded by controversy or uncertainty and 100 
have led to a thorough revision of clinical practice in recent years 1. For example, genital 101 
surgery in young children is more often avoided nowadays in order to protect childrens’ rights 102 
of an open future and integrity of the body; and increasing numbers of children grow up with 103 
atypical-looking genitalia, of which the psychological impact is not known 9. Many DSD teams 104 
provide psychological support to affected families as a standard component of care 105 
nowadays, children are informed early about their condition, and gender issues are openly 106 
discussed 6. Some teams include peer support in the medical management plan 10. 107 
Structured longitudinal assessment of individuals with a DSD across centres may provide 108 
future evidence in favour or against these new practices, with specific relevance to (rare) 109 
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individual diagnoses, provided that all relevant parameters are considered in parallel and by 110 
standardized measurement tools.  111 
In accordance with patient aspirations, the promotion of a standardized protocol that uses a 112 
non-binary vocabulary and medical approach can be paramount in inducing societal change 113 
as well as amongst the medical community, in attitudes towards gender perception and 114 
normative paradigms of sex, including genital characteristics 11. This will by itself be 115 
instrumental in defining the place, timing and the specific medical need of genital surgery.  116 
 117 
2. Development of consensus on standardised data collection 118 
The development of a meaningful, holistic schedule for clinical assessment that allows for 119 
standardized longitudinal data collection over time in individuals who have a DSD has been 120 
the primary goal of an expert multidisciplinary working group, including representatives from 121 
patient support groups. This group operated in the period 2013 – 2017 in the framework of 122 
the European Cooperation in Science and Technology (COST) Action BM1303 “DSDnet” 123 
(www.DSDnet.eu), funded by the European Union Horizon 2020 program. Collaboratively, 124 
the group: 1) reviewed the literature on existing instruments for clinical phenotyping at all 125 
ages; 2) defined their major strengths and shortcomings as well as hitherto insufficiently 126 
covered areas of (para)medical attention; and 3) discussed essential characteristics of a 127 
qualitative longitudinal follow-up program until agreement was reached on a protocol for 128 
standardised assessment at various ages that was versatile enough to be used in clinical 129 
settings as well as within electronic global platforms such as the I-DSD registry. 130 
 131 
3. General dataset and ages at which follow-up assessments are recommended 132 
Criteria for referral of a child for expert evaluation are specified in the UK guidelines 12. At 133 
first referral, linking the case to original health records and obtaining consent for sharing data 134 
(local, national, international) are crucial. Basic DSD-related information, such as diagnosis, 135 
karyotype, birth-assigned sex, and social gender should also be included (Table 1). 136 
Thereafter, appropriate time intervals for clinical revision of patients depend on the 137 
respective conditions, patient age, and individual circumstances. However, for registration 138 
and research purposes, it was considered crucial to standardise a minimal set of time points, 139 
corresponding to important developmental milestones, at which relevant clinical data should 140 
be collected (Figure 1).  141 
A summary of neonatal data, where available, should be collected in all cases with later 142 
presentation (Table 2). Clinical revision at age 4 years (Table 3) allows for comprehensive 143 
assessment of psychological developmental milestones, associated symptoms, and growth 144 
patterns, including catch-up growth. The process of informing the child about the condition 145 
should start as soon as possible after diagnosis, along with the provision of support in 146 
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acquiring a vocabulary to talk about the DSD 13. Practical advice on this matter can be found 147 
at support group resources (e.g. www.dsdfamilies.org or https://www.iglyo.com/wp-148 
content/uploads/2018/10/Supporting-Your-Intersex-Child.pdf). At age 8 years (Table 3), 149 
relevant information on growth and development shortly before start of puberty can be 150 
obtained. At this age the child understands more complex information about how the body 151 
functions and about the specific DSD. Gender identity or eventual dysphoria may be 152 
ascertained and children experiencing uncertainty can be referred for expert psychological or 153 
psychiatric evaluation and support. Pubertal development and progression (Table 4) may be 154 
compromised in many children who have a DSD. Some children may need hormonal 155 
induction of puberty. Standardized assessment at start of puberty and the outcome of 156 
pubertal development are therefore paramount to document, though most children will need 157 
clinical revision more frequently. Transition to adult healthcare should be discussed early on 158 
during this period 8, 14.   159 
Much less evidence is available to guide timing of clinical revision in adulthood (Table 5). In 160 
favour of standardized assessment of young individuals aged 18-25 is that they are in the 161 
process of gaining independence and have recently transitioned to adult care. Many young 162 
people are newly forming intimate relationships, which potentiates new concerns and/or 163 
required healthcare intervention. Topics such as sexual function, sexual orientation, and 164 
gender identity may become central in their lives. In addition, baseline information on typical 165 
health issues in adulthood such as bone mineral density, blood pressure, and obesity should 166 
be collected. Issues around fertility and forming a family may dominate between ages 25 and 167 
40.  168 
During the age intervals of 40-60 and 60-80, long-term effects of treatment or (lack of) 169 
hormonal treatment and co-morbidities may become apparent 8. Physical and mental health 170 
issues of adults living with a DSD are major determinants of overall quality of life (QoL) 4. It is 171 
therefore crucial to capture such information in order to allow for future research and 172 
appropriate management.   173 
    174 
4. Genetic and biochemical data 175 
Most causes of DSD are genetic; however, drugs, environmental toxins, and maternal and 176 
placental causes are also relevant and/or may influence outcomes. A clear diagnosis can 177 
determine the spectrum of potentially affected organs, current/future health consequences, 178 
and treatment options 8.  179 
A comprehensive diagnostic approach consists of an extensive family history over at least 3 180 
generations, as well as a physical exam of the whole body which includes the genital organs. 181 
This will then guide the clinician towards further diagnostic imaging, biochemical and genetic 182 
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studies. Guidelines for the clinical, biochemical, and genetic work-up of DSD have been 183 
published elsewhere 12, 15, 16.    184 
Collecting genetic information, together with clinical and biochemical data, in a centralized 185 
registry allows identification and characterization of DSD subgroups, including those for 186 
which a genetic diagnosis has not been achieved so far. It is possible then to test the 187 
diagnostic reliability of specific biochemical and genetic parameters and their usefulness for 188 
implementation in clinical diagnostic guidelines. It will also enable studies on the impact of a 189 
molecular genetic diagnosis on outcome. Indeed, almost 50% of individuals who have a 190 
46,XY DSD have no genetic diagnosis, and it remains debatable whether and how this 191 
impacts management and overall quality of life 17.  192 
Although DSDs are congenital conditions, the function of affected organs may decline over 193 
time, e.g. testicular function in 45,X/46,XY boys 18. Therefore, any initially performed 194 
diagnostic laboratory investigation may need to be repeated, if in doubt and of therapeutic 195 
consequence. Hormonal and other drug treatments need to be controlled with regular 196 
intervals for correct dosing, effectiveness and side effects. Biochemical parameters that 197 
qualify best for treatment monitoring need to be identified based on prospectively collected 198 
data.  199 
In some individuals who have an unknown cause of their condition, genetic work-up has 200 
been performed years ago with methods that are currently outdated. In others, whole exome 201 
or whole genome sequencing may reveal variants of unknown significance or monogenetic 202 
variants in established DSD genes that do not clearly explain the observed phenotype (e.g. 203 
heterozygous MAMLD1 mutations) 19. Finally, DSD genetics may be more complex than 204 
initially thought, as demonstrated recently 20. Therefore, genetic results may also require re-205 
evaluation as new knowledge is gained over time.  206 
 207 
5. Medical fields  208 
5.1 Family data 209 
A detailed family history, including fertility is essential to explore possible inheritance 210 
mechanisms and to lend support for molecular genetic investigations in individuals with 211 
milder phenotypes. Phenotypic variability within families may be broad and may comprise 212 
subfertility/infertility as the only sign, depending on the severity of the mutation 21, 22. 213 
 214 
5.2 Associated conditions 215 
Several co-morbidities and non-gonadal organ dysfunctions are associated with specific 216 
DSDs 23.  Further exploration of these associations is important for targeted follow-up of 217 
affected individuals and for understanding mechanisms of disease. As many DSD conditions 218 
are caused by mutations in transcription factors that regulate the development of several 219 
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organ systems, this may result in combined functional defects, as for example in WT1 220 
(kidney involvement), NR5A1 (adrenal involvement, spleen hypoplasia) or GATA4 (cardiac 221 
defects) mutations 24-27. Associated conditions are mostly found in chromosomal DSD such 222 
as 45,X/46,XY and may only develop over time, requiring medical attention at each follow-up 223 
visit, for example cardiac surveillance in all individuals who have 45,X/46,XY mosaicism 18, 28.   224 
  225 
5.3 External and internal genital phenotype 226 
As genital photography and storage faces ethical and legal challenges, standardized tools 227 
are needed to objectively describe the genital aspect in detail. Qualitative visual scales such 228 
as the Prader 29 or Quigley 30 scales are highly observer-dependent and do not consider 229 
internal and external genital status separately. The anogenital distance correlates with 230 
prenatal androgen exposure but lacks standardization and is difficult to perform in children 231 
above one year 31. The External Masculinization Score (EMS) is a practical and objective 232 
tool, has good inter-observer reliability and correlates with relevant clinical outcomes 12, 32, 33. 233 
Limitations include its restricted applicability – only male neonates - and dichotomous nature 234 
(e.g. micropenis yes/no). To overcome these problems, a modified EMS, termed “external 235 
genitalia score” (EGS), has been developed. The EGS assesses the same anatomical 236 
landmarks as EMS while using a gender-neutral vocabulary applicable in all infants up to two 237 
years of age, and a more gradual scale, reflecting the naturally occurring phenotypic 238 
variability of external genitalia. Reference ranges for a mixed European population have 239 
been determined 34. Additional parameters such as penile curvature and tissue quality are 240 
likely related to (surgical) outcome, but these are currently ill-defined and require further 241 
study. Reliable assessment of internal genitalia requires imaging and sometimes surgical 242 
procedures such as laparoscopy. Knowledge on the internal anatomy can be helpful in cases 243 
where the initial sex/gender of rearing is unclear and to foresee possible complications. 244 
Imaging techniques have significant differences in sensitivity, sensibility, and invasiveness. In 245 
the longer term, meta-analysis of data will provide further insights on the procedure of choice 246 
in specific situations.  247 
The genital phenotype and other sex characteristics change as the individual grows or as a 248 
result of hormonal treatment or surgery. Frequent genital inspection is not recommended, but 249 
may be helpful in specific situations, especially as it can help parents and children / 250 
adolescents to understand that there is a natural variation in clitoral sizes and genital aspect 251 
or to discuss eventual parental or patient worries. For example, in 46,XX individuals who 252 
have CAH, clitoral size may decrease in response to glucocorticoid treatment after the 253 
newborn period. This finding is often very reassuring for parents and may actually convince 254 
them that the genital aspect has indeed become unremarkable for a lay person taking care of 255 
their baby. On the other hand, clitoral size may increase in periods of undertreatment or non-256 
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compliance 35, 36 and/or adolescent girls may feel insecure about its aspect. Thoughtful 257 
genital inspection in an adolescent girl, after having obtained her consent, may sometimes 258 
help her discussing eventual worries about the genital aspect and/or reassure her that clitoral 259 
sensitivity is most important and that the clitoral aspect falls within the natural variation. 260 
Gonadal failure may result in lack or arrest of pubertal development. In such cases, it is 261 
important to document genital pubertal progression at the suggested time intervals. 262 
Suspicion of complications, e.g. fistulae after hypospadias surgery will also require a genital 263 
exam.     264 
In adult life, psychosexual function is an even more important outcome parameter and should 265 
be discussed as suggested in Table 5; sometimes, depending on the  specific question (eg 266 
worries about penile length), this will need to be done in parallel with a genital exam 1, 36.  267 
 268 
5.4 Anthropometric data, body composition and bone health 269 
Documentation of birth weight and length, growth, body composition and bone health 270 
parameters is crucial as it may reveal long-term outcomes of childhood processes such as 271 
the postnatal hypothalamic-pituitary-gonadal activation (the “mini-puberty”) and growth 272 
patterns in DSD other than Turner syndrome (TS) and Klinefelter syndrome (KS), where 273 
evidence is currently scarce. For example, no data are available on the prevalence and 274 
extent of catch-up growth in children with atypical genitalia who were born small for 275 
gestational age. In individuals with 45X/46XY karyotypes, growth hormone treatment has 276 
variable effects and may need to be optimised 37, 38.  Age at start of puberty induction and 277 
dosing of sex steroids may affect the growth pattern and body proportions 39. Glucocorticoid 278 
overtreatment compromises growth and leads to increased weight and BMI in the longer 279 
term 40. Both androgens and estrogens are important for bone mass accrual and 280 
maintenance. Overtreatment with glucocorticoids, vitamin D deficiency, physical activity, and 281 
hereditary factors may influence bone health 41.  282 
 283 
5.5 Medical treatments 284 
Some treatments are offered early in life, but evidence of their long-term efficacy may be 285 
lacking, e.g. testosterone (T) or dihydrotestosterone (DHT) for micropenis 42. The use of 286 
some medications is experimental (e.g. aromatase inhibitors to block the effect of sex 287 
hormones 43, 44 or metformin to avoid metabolic consequences 45), but others, such as growth 288 
hormone, gluco- and mineralocorticoids, L-thyroxin, insulin and sex hormone replacement 289 
therapy are frequently used in DSD and need constant surveillance and adjustments 46-48. 290 
Standardized guidelines are lacking for most DSD conditions, with the exception of TS and 291 
KS 46, 49.   292 
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Lifelong steroid and sex hormone replacement therapy may induce side effects that 293 
negatively (or positively) impact QoL 4 and optimal dosing may vary with age  50, 51. Very few 294 
studies address medical needs to optimise sexual function and to avoid secondary health 295 
consequences, especially at older ages. In addition, treatment regimens differ widely across 296 
centres and comparison of these protocols may further improve patient management and 297 
health-related QoL in the future 2, 52. Large-scale registration and in-depth analysis of co-298 
morbidities and of chronic use of certain medications aim to improve care and to positively 299 
alter outcomes. 300 
Particular attention has been given to the prenatal treatment of a foetus possibly affected by 301 
21-hydroxylase deficiency with dexamethasone administered to the mother. Benefit-risk ratio 302 
is still unclear and it is currently regarded as experimental 36. From another perspective, 303 
drugs such as pain killers given to pregnant women and (environmental) toxins may affect 304 
foetal sexual development and fertility 53. This important domain is largely unexplored, and 305 
collecting detailed information related to this topic is essential for future exploration. 306 
 307 
5.6 Fertility and documentation of gonadal cancers 308 
Fertility is strongly reduced in all forms of DSD, for biological and/or psychosocial reasons. 309 
Contemporary assisted reproductive techniques (ART) can increase chances to have 310 
biological children for some azoospermic individuals with 46,XY DSD and for some who have 311 
viable eggs 54, 55. Uterus transplantations have resulted in live births 56. It is anticipated that 312 
improvement of hormonal therapies and new technologies (e.g. in vitro generation of induced 313 
primordial germ cell-like cells) 57 may further increase fertility rates in the future. Assessment 314 
and documentation of reproductive capacity of the gonads independent of the patients’ social 315 
gender has the aim of understanding condition-specific fertility chances 58. It can also 316 
facilitate access to international research protocols in this field through recruitment of 317 
registered patients.     318 
The mechanisms underlying germ cell cancer development in DSD are increasingly 319 
understood. Routine prophylactic gonadectomy to prevent germ cell cancer development is 320 
no longer recommended in all individuals at risk; guidelines for selective gonadectomy and 321 
surveillance of retained gonads have been published 59, 60. Given the recent practice 322 
changes, no long-term outcome data on tumour risk in adulthood are available today, and 323 
with the possible exception of complete androgen insensitivity 60, 61, individualized 324 
management is hampered by a paucity of condition-specific data 59, 62. Therefore, current 325 
recommendations may need to be adjusted based on future insights. With a molecular 326 
genetic diagnosis more often reached today, and with systematic registration of pathology 327 
results and centralized review of challenging cases, further progress in this matter can be 328 




6. Surgical fields  331 
6.1 Childhood surgery  332 
There are few evidence-based indications for gonadal or genital surgery in early childhood. 333 
Gonadal biopsy may, in exceptional cases, support important decisions, e.g. in relation to 334 
sex of rearing in the context of suspected (ovo)testicular DSD 64. Following international 335 
criticism of early genital surgery, many centers have restricted such procedures 9. Although 336 
debated, early surgery is still offered by some centres for 46,XX CAH patients with severe 337 
genital virilization and for 46,XY patients with hypospadias. Other centers have restricted 338 
such procedures and consider alternative options such as raising severely virilised 46,XX 339 
CAH children as males and offer extensive parental support to enhance the information and 340 
decision–making process. The developmental, familial, and societal impact of growing up 341 
with atypical-looking genitalia is currently not well understood. Psychosocial support appears 342 
crucial, and detailed documentation of such decisions in a multicentre registry is essential to 343 
allow urgent studies on their appropriateness and long-term consequences 65. Systematic 344 
registration can also demonstrate the time and pace needed to definitively implement the 345 
proposed practice changes.   346 
There is no scientific evidence nor expert consensus on how surgery or refraining from 347 
surgery impacts the individual, family, society, or risk of stigmatization 1. Standardized and 348 
detailed documentation of performed procedures, complications and reasons for and 349 
outcome of (non-) intervention are therefore crucial 9. As the focus of many performed genital 350 
surgeries nowadays is more on function than in relation to gender assignment, a specific 351 
description should be used for the intervention or the reasons to intervene rather than 352 
referring to “feminising / masculinizing” genital surgery. 353 
 354 
6.2 Genital examinations  355 
Genital examinations should be limited and should have a clear and transparent purpose. 356 
Living with atypical-looking genitals and/or having had genital surgery may pose 357 
psychological and psychosexual challenges that require timely referral to a psychologist or 358 
sexologist. This person can then further perform a psychological evaluation, using 359 
standardized diagnostic measures and propose appropriate support if needed. The applied 360 
methodology depends on the specific goal of such an assessment. No DSD-specific 361 
questionnaires to assess psychological and/or psychosexual functioning currently exist, and 362 
interpretation of results is seriously hampered by methodological limitations, highlighting the 363 
need for psychologists with good knowledge of and experience with the various conditions 364 




6.3 Follow-up of adults  367 
Follow-up of adults who had genital surgery in infancy is rarely organized in the routine 368 
clinical setting. High-quality outcome and longitudinal studies are scarce. Difficulties include 369 
differences in technical terms, modifications of surgical techniques over the years,  370 
heterogeneity of DSD conditions and reporting bias of surgeons towards the techniques they 371 
are most experienced with 67. Comprehensive assessment ideally includes recording 372 
complications and redo surgery (also in adulthood), cosmetic appearance, functional 373 
outcome (micturition, sexuality), and quality of psychosexual life as a minimum, all in relation 374 
to preoperative findings and assessed both by a professional and by self-assessment 68-71.  375 
The hypospadias objective penile evaluation score (HOPE) has been designed for 376 
standardized cosmetic evaluation by a professional of hypospadias surgery 72. Although 377 
practical and objective, HOPE has important shortcomings, such as the use of genital 378 
pictures, lack of evaluation of the scrotum and of possibilities for self-assessment, most 379 
notably of penile size, which is considered crucial by many patients 73. A subjective cosmetic 380 
evaluation of hypospadias surgery can be obtained with the penile perception score (PPS) 381 
and its paediatric variant (PPPS) 74, 75. All the above lack functional parameters such as 382 
micturition pattern, and erection and ejaculation capacity. A suggestion for a non-383 
photography based modified HOPE score, with addition of relevant functional and self-384 
perceived assessments is provided in Supplementary Table 1.  385 
Different measures have been used for gynaecological and sexual function assessments of 386 
the female genitalia (e.g. 67, 71, 76). Standardized tools for assessing long-term functional and 387 
cosmetic outcome of female genital surgery are in development. Items that are important to 388 
assess are listed in Supplementary Table 2. 389 
 390 
7. Psychosocial fields 391 
Trends in sex assignment have changed over the years 33. Sex and gender are fundamental 392 
in the development of a person’s identity, as well as the individual’s integrity, self-esteem, 393 
and social relations. Inappropriate focus or a normative perspective on genital, sexual, and 394 
psychological issues may cause annoyance or stigmatization. Therefore, questions about a 395 
person’s gender experience and gender well-being should be posed with respect for the 396 
individual’s integrity and in an open-ended way that does not presume a particular gender, or 397 
increase shame and stigma 66. Both children and adolescents should be given the possibility 398 
to talk about these issues without a parent being present 13.  399 
Assessment of an individual’s mental well-being and need for psychosocial support should 400 
be part of standard care throughout life. Physical or mental health problems are highly 401 
prevalent in individuals who have a DSD 2, 8. Importantly, not the specific diagnosis but the 402 
personal health status predicts quality of life (QoL) 4. Overall, individuals with a DSD report 403 
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good QoL but studies are often contradictory, possibly due to differences in local treatment 404 
and care, age and cultural context and differences in methodology. Appropriate QoL 405 
questionnaires should focus on social and psychological domains that are relevant for 406 
individuals who have a DSD 77. In addition, patient reported outcome measures related to 407 
QoL at all life stages are considered most crucial by patients and it is clear that they have a 408 
central place in holistic care 78. Formal QoL assessment in the context of routine clinical 409 
practice is unusual, but as a minimum, it is suggested to record the impact of the condition 410 
on the patients’ daily life by including a relevant proxy for this. While awaiting more specific 411 
key questions, preferably developed by support groups and other stakeholders, a generic set 412 
of simple questions is proposed here, that can be adjusted to all ages.  413 
Considering all conditions together, the prevalence of gender dysphoria is only slightly 414 
increased in DSD. However, assessing gender identity and gender-related behaviour 415 
according to a strict binary or pathologising model will insufficiently capture the broad 416 
spectrum of gender-related outcomes 79. Currently, hardly any instrument is available that 417 
allows gender assessment according to a spectral rather than a bimodal paradigm. 418 
Therefore, new measures and instruments, using a non-binary vocabulary and taking all 419 
possible gender outcomes into account need to be developed. In addition, gender role 420 
behaviour rather than gender well-being has been given (too) much attention in the past. 421 
Indeed, it is crucial not to misinterpret behaviour or sexual orientation as signs of gender 422 
dysphoria 11.  423 
From the beginning, psychosocial support for parents, aiming at an enhanced understanding 424 
of the medical context and the diagnostic investigations are crucial factors for coping with 425 
psychological distress 80. Parent-child bonding, coping abilities and symptoms of stress are 426 
important indicators of parental needs on this matter 12. In the presence of a genital 427 
difference, parents need guidance on how to raise resilient children and how to communicate 428 
early with their child about the condition, including consequences for gender development 429 
and past and future treatment options 81. To what extent psychosocial support and early 430 
information may contribute to optimization of outcomes has never been documented in the 431 
context of DSD. Providing further evidence in favour of such support may convince policy 432 
makers to invest in psychological counselling, as an important part of preventive care and as 433 
a valuable alternative to genital surgery, amongst others 82, 83.  434 
Many registries such as I-DSD are developing sections that include possibilities for self-435 
reporting of relevant outcome measures, such as reasons for genital surgery or not having 436 
such surgery, and self-reported QoL. Altogether, considering the voices of people with DSD 437 
and their parents, research and care of DSD can move from a researcher driven to a 438 




Conclusions and Perspectives 441 
Consensus was reached on standardized assessments of individuals who have a DSD and 442 
on the ages at which clinical revision should be performed in order to capture crucial 443 
developmental milestones and/or long-term consequences of the various conditions. In the 444 
clinical setting, the tool will ensure and support a high quality of clinical care. Long-term and 445 
wide use of this instrument, e.g. through the I-DSD Registry, will allow answering critical 446 
research questions in the future specifically in relation to outcome, treatment options, 447 
comorbidities in adult age and fertility. In addition, patient reported outcome measures, 448 
obtained through patient portals, are expected to become increasingly important and may be 449 
also implemented in the i-dsd registry in the near future.   450 
 451 
 452 
Figure Legend and Tables’ List: 453 
Figure 1 – Scheme of the longitudinal I-DSD registration tool showing time points, ages for 454 
data entry, starting at the age of diagnosis. Neonatal data, including genetic information if 455 
available, should always be entered regardless of the age at diagnosis. 456 
 457 
Table 1 - Neonatal assessment (within first month of birth) 458 
Table 2 - Clinical assessment (at any age if first assessment after 1 month of age) 459 
Table 3 - Table 3. Childhood assessment (at age 4 years and 8 years) 460 
Table 4 - Table 4. Adolescent assessment (at start of puberty and end of puberty) 461 
Table 5 - Table 5: Adult assessment (once per interval: 18-25; 25-40; 40-60; 60-75 years) 462 
 463 
Supplementary Table1 - Tool for assessment of hypospadias (repair) 464 
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Table 1. Neonatal assessment (within first month of birth) 
General      
Date of Assessment 
dd/mm/yyyy 





Height, cm BMI, kg/m2 Mothers Height, cm Fathers Height, cm Mid Parental Height, cm 
Original Sex Assigned 




Male/ Female/ Both/ Not 
assigned/ Other 
Child raised as 






External Phenotype      
Meatus 
Typical female/ Perineal/ Scrotal/ 
Penoscrotal/ Penile/ Coronal/ 
Typical male 
Left Gonad Location 
Impalpable/ Inguinal/ 
Inguinoscrotal/ Labioscrotal 
Right Gonad Location 
Impalpable/ Inguinal/ 
Inguinoscrotal/ Labioscrotal 
Genital Tubercle Length, mm 
<10/ 10-20/ 21-25/ 26-30/ >30 
 
Phallus Size 
Within/ Below/ Above the 
reference range for male; 
Within/ Below/ Above the 




Anogenital Distance 1# (AGD1), 
mm 
 
Anogenital Distance 2## (AGD2), 
mm 
External Masculinisation Score 
(EMS) 
External Genitalia Score (EGS)   
Internal Phenotype      
Imaging Modality- Left Gonad 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Imaging Modality- Right Gonad 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Gonad Morphology 
Absent/ Streak/ Testis/ Ovary/ 
Ovotestis/ Other 
Right Gonad Morphology 
Absent/ Streak/ Testis/ Ovary/ 
Ovotestis/ Other 
Imaging Modality- Uterus 





Normal/ Not known 
 
Imaging Modality- Left Fallopian 
Tube 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
 
Imaging Modality- Right 
Fallopian Tube 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Fallopian Tube 
Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
Right Fallopian Tube 
Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
Distance- Vaginal 
Confluence to Bladder 
Neck, cm 
Distance- Vaginal 
Confluence to Introitus, cm 
Imaging Modality- Left Vas 
Deferens 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Imaging Modality- Right Vas 
Deferens 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Vas Deferens Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
Right Vas Deferens Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
  
Surgery      
Left Gonad Biopsy 
Yes/ No/ Not known 
 
Right Gonad Biopsy 
Yes/ No/ Not known 
 
Left Gonadectomy 
Yes/ No/ Not known 
 
Right Gonadectomy 




None/ clitoral surgery / 
vaginal surgery / 
labioscrotal surgery / 
hypospadias surgery / 
urethral surgery other than 
hypospadias; age 
 
Reasons for genital 
reconstructive surgery 
Functional / cosmesis / both 
 
Post Surgical Complications  
Yes/ No/ Not known; if yes, 
describe. 
Psychosocial      
Change in Legal Sex 
Yes/ No/ Not known 
Psychosocial Support Offered to 
Parents 
Yes/ No/ Not known 
 
Ongoing Psychosocial Support 
Yes/ No/ Not known 
 
   
Medication      
Testosterone 




Yes (IM, Oral, Transdermal)/ No/ 
Not known 
Aromatase Inhibitor 
Yes/ No/ Not known 
GnRH analogues 
Yes/ No/ Not known 
Glucocorticoids 
Yes/ No/ Not known 
Fludrocortisone 
Yes/ No/ Not known 
Oestrogen 
Yes (IM, Oral, Transdermal)/ No/ 
Not known  
 
Other Drugs 
Yes/ No/ Not known 
    
Lab Tests      
LH 
Low/ Normal/ High/ Not known 
 
FSH 
Low/ Normal/ High/ Not known 
 
AMH 
Low/ Normal/ High/ Not known 
 
Inhibin B 
Low/ Normal/ High/ Not known 
 
Androstenedione 








Low/ Normal/ High/ Not known 
 
Dihydrotestosterone 
Low/ Normal/ High/ Not known 
 
Oestradiol 
Low/ Normal/ High/ Not known 
 
17-OHP 










Low/ Normal/ High/ Not known 
 
Total Testosterone 
Low/ Normal/ High/ Not known 
 
Dihydrotestosterone 
Low/ Normal/ High/ Not known 
 
  
Adrenal Stimulation Test 
Specify protocol 
17-OHP 
Low/ Normal/ High/ Not known 
 
11-deoxycortisol 
Low/ Normal/ High/ Not known 
 
Pregnenolone 
Low/ Normal/ High/ Not known 
 
17-OH Pregnenolone 
Low/ Normal/ High/ Not 
known 
DHEA 
Low/ Normal/ High/ Not 
known 
*Associated conditions: CNS, Heart, Renal, Skeletal, Skin, ENT, Eyes, Blood and Lymp, Craniofacial, Adrenal, GI Tract, Haematological, Respiratory, SGA (Small for Gestational Age), Short 
stature, Non-defined syndrome, Other. ** Genital reconstructive surgery field may be repeated. 




Table 2. Clinical assessment (at any age if first assessment after 1 month of age) 
General      
Date of Assessment 
dd/mm/yyyy 





Height, cm BMI, kg/m2 Mothers Height, cm Fathers Height, cm Mid Parental Height, cm 
Original Sex Assigned 




Male/ Female/ Both/ Not 
assigned/ Other 
Child raised as 






External Phenotype      
Meatus 
Typical female/ Perineal/ Scrotal/ 
Penoscrotal/ Penile/ Coronal/ 
Typical male 
Left Gonad Location 
Impalpable/ Inguinal/ 
Inguinoscrotal/ Labioscrotal 
Right Gonad Location 
Impalpable/ Inguinal/ 
Inguinoscrotal/ Labioscrotal 
Genital Tubercle Length, mm 
<10/ 10-20/ 21-25/ 26-30/ >30 
 
Phallus Size 
Within/ Below/ Above the 
reference range for male; 
Within/ Below/ Above the 




Anogenital Distance 1# (AGD1), 
mm 
 
Anogenital Distance 2## (AGD2), 
mm 
External Masculinisation Score 
(EMS) 
External Genitalia Score (EGS)   
Internal Phenotype      
Imaging Modality- Left Gonad 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Imaging Modality- Right Gonad 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Gonad Morphology 
Absent/ Streak/ Testis/ Ovary/ 
Ovotestis/ Other 
Right Gonad Morphology 
Absent/ Streak/ Testis/ Ovary/ 
Ovotestis/ Other 
Imaging Modality- Uterus 





Normal/ Not known 
 
Imaging Modality- Left Fallopian 
Tube 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
 
Imaging Modality- Right 
Fallopian Tube 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Fallopian Tube 
Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
Right Fallopian Tube 
Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
Distance- Vaginal 
Confluence to Bladder 
Neck, cm 
Distance- Vaginal 
Confluence to Introitus, cm 
Imaging Modality- Left Vas 
Deferens 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Imaging Modality- Right Vas 
Deferens 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Vas Deferens Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
Right Vas Deferens Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
  
Surgery      
Left Gonad Biopsy 
Yes/ No/ Not known 
 
Right Gonad Biopsy 
Yes/ No/ Not known 
 
Left Gonadectomy 
Yes/ No/ Not known 
 
Right Gonadectomy 




None/ clitoral surgery / 
vaginal surgery / 
labioscrotal surgery / 
hypospadias surgery / 
urethral surgery other than 
hypospadias; age 
Reasons for genital 
reconstructive surgery 
Functional / cosmesis / both 
 
Post Surgical Complications  
Yes/ No/ Not known; if yes, 
describe 
Psychosocial      
Change in Legal Sex 
Yes/ No/ Not known 
Psychosocial Support Offered to 
Parents 
Yes/ No/ Not known 
 
Ongoing Psychosocial Support 
Yes/ No/ Not known 
 
   
Medication      
Testosterone 




Yes (IM, Oral, Transdermal)/ No/ 
Not known 
Aromatase Inhibitor 
Yes/ No/ Not known 
GnRH analogues 
Yes/ No/ Not known 
Glucocorticoids 
Yes/ No/ Not known 
Fludrocortisone 
Yes/ No/ Not known 
Oestrogen 
Yes (IM, Oral, Transdermal)/ No/ 
Not known  
 
Other Drugs 
Yes/ No/ Not known 
    
Lab Tests      
LH 
Low/ Normal/ High/ Not known 
 
FSH 
Low/ Normal/ High/ Not known 
 
AMH 
Low/ Normal/ High/ Not known 
 
Inhibin B 
Low/ Normal/ High/ Not known 
 
Androstenedione 








Low/ Normal/ High/ Not known 
 
Dihydrotestosterone 
Low/ Normal/ High/ Not known 
 
Oestradiol 
Low/ Normal/ High/ Not known 
 
17-OHP 










Low/ Normal/ High/ Not known 
 
Total Testosterone 
Low/ Normal/ High/ Not known 
 
Dihydrotestosterone 
Low/ Normal/ High/ Not known 
 
  
Adrenal Stimulation Test 
Specify protocol 
17-OHP 
Low/ Normal/ High/ Not known 
11-deoxycortisol 
Low/ Normal/ High/ Not known 
Pregnenolone 
Low/ Normal/ High/ Not known 
17-OH Pregnenolone  DHEA  
   Low/ Normal/ High/ Not 
known 
 




*Associated conditions: CNS, Heart, Renal, Skeletal, Skin, ENT, Eyes, Blood and Lymp, Craniofacial, Adrenal, GI Tract, Haematological, Respiratory, SGA (Small for Gestational Age), Short 
stature, Non-defined syndrome, Other. ** Genital reconstructive surgery field may be repeated. 
# AGD 1: Distance from the centre of the anus to the posterior base of the labioscrotal folds; ##AGD 2: Distance from the centre of the anus to the anterior base of the phallus 
 
Table 3. Childhood assessment (at age 4 years and 8 years) 
General      
Date of Assessment 
dd/mm/yyyy 
 
Age at Assessment, years Weight, kg 
 
Height, cm BMI, kg/m2 
 
Mothers Height, cm 
Fathers Height, cm Mid Parental Height, cm Original Sex Assigned 




Male/ Female/ Both/ Not 
assigned/ Other 
Child raised as 




Bone Age      
Bone Age Date 
dd/mm/yyyy 
Bone Age Result, years Bone Age Method 
TW20/ Radius-ulna-short bone/ 
Greulich & Pyle 
 
   
External Phenotype      
Meatus 
Typical female/ Perineal/ 
Scrotal/ Penoscrotal/ Penile/ 
Coronal/ Typical male 
Left Gonad Location 
Impalpable/ Inguinal/ 
Inguinoscrotal/ Labioscrotal 
Right Gonad Location 
Impalpable/ Inguinal/ 
Inguinoscrotal/ Labioscrotal 
Genital Tubercle Length, mm 
<10/ 10-20/ 21-25/ 26-30/ >30 
 
Phallus Size 
Within/ Below/ Above the 
reference range for male; 
Within/ Below/ Above the 




External Masculinisation Score 
(EMS) 
 
External Genitalia Score (EGS)     
Internal Phenotype      
Imaging Modality- Left Gonad 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Imaging Modality- Right Gonad 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Gonad Morphology 
Absent/ Streak/ Testis/ Ovary/ 
Ovotestis/ Other 
Right Gonad Morphology 
Absent/ Streak/ Testis/ Ovary/ 
Ovotestis/ Other 
Imaging Modality- Uterus 





Normal/ Not known 
 
Imaging Modality- Left 
Fallopian Tube 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
 
Imaging Modality- Right 
Fallopian Tube 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Fallopian Tube 
Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
Right Fallopian Tube 
Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
Distance-Vaginal Confluence 
to Bladder Neck by Imaging, 
cm 
Distance- Vaginal 
Confluence to Introitus by 
Imaging, cm 
Imaging Modality- Left Vas 
Deferens 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
 
Imaging Modality- Right Vas 
Deferens 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Vas Deferens Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
Right Vas Deferens Morphology 
Absent/ Rudimentary/ Normal/ 
Not known 
  
Surgery      
Left Gonad Biopsy 
Yes/ No/ Not known 
 
Right Gonad Biopsy 
Yes/ No/ Not known 
 
Left Gonadectomy 
Yes/ No/ Not known 
 
Right Gonadectomy 




None/ clitoral surgery / 
vaginal surgery / labioscrotal 
surgery / hypospadias surgery 
/ urethral surgery other than 
hypospadias; age 
 
Reasons for genital 
reconstructive surgery 
Functional / cosmesis / both 
 
Post Surgical Complications  
Yes/ No/ Not known; if yes, 
describe 
Psychosocial, Gender Identity      
Any Change in Legal Sex 
Yes/ No/ Not known 
Psychosocial Support Offered to 
Parents 
Yes/ No/ Not known 
 
Ongoing Psychosocial Support 
for Parents 
Yes/ No/ Not known 
 
Psychosocial Support Offered to 
Child 




Support for Child 
Yes/ No/ Not known 
 
Age-appropriate 
Information to Child 
Yes/ No/ Not known 
 
Has Child Questioned Their 
Gender  
Yes/ No/ Not known 
 
Is Child Distressed About Gender 
Identity or Assignment 
Yes/ No/ Not known 
 
    
Medication      
Testosterone 
Yes (IM, Oral, Transdermal)/ 
No/ Not known 
 
DHT 
Yes (IM, Oral, Transdermal)/ No/ 
Not known 
Aromatase Inhibitor 
Yes/ No/ Not known 
GnRH analogues 
Yes/ No/ Not known 
Glucocorticoids 
Yes/ No/ Not known 
Fludrocortisone 
Yes/ No/ Not known 
Oestrogen 
Yes (IM, Oral, Transdermal)/ 
No/ Not known  
 
Other Drugs 
Yes/ No/ Not known 
    
Lab Tests      
LH 
Low/ Normal/ High/ Not known 
FSH 
Low/ Normal/ High/ Not known 
AMH 
Low/ Normal/ High/ Not known 
Inhibin B 
Low/ Normal/ High/ Not known 
Androstenedione Total Testosterone 
    Low/ Normal/ High/ Not 
known 
 




Low/ Normal/ High/ Not known 
 
Dihydrotestosterone 
Low/ Normal/ High/ Not known 
 
Oestradiol 
Low/ Normal/ High/ Not known 
 
17-OHP 










Low/ Normal/ High/ Not known 
 
Total Testosterone 
Low/ Normal/ High/ Not known 
 
Dihydrotestosterone 
Low/ Normal/ High/ Not known 
 
  
Adrenal Stimulation Test 
Specify protocol 
17-OHP 
Low/ Normal/ High/ Not known 
 
11-deoxycortisol 
Low/ Normal/ High/ Not known 
 
Pregnenolone 
Low/ Normal/ High/ Not known 
 
17-OH Pregnenolone 
Low/ Normal/ High/ Not 
known 
DHEA 
Low/ Normal/ High/ Not 
known 
*Associated conditions: CNS, Heart, Renal, Skeletal, Skin, ENT, Eyes, Blood and Lymp, Craniofacial, Adrenal, GI Tract, Haematological, Respiratory, SGA (Small for 
Gestational Age), Short stature, Non-defined syndrome, Other. ** Genital reconstructive surgery field may be repeated. 
 
Table 4. Adolescent assessment (at start of puberty and end of puberty) 
General      
Date of Assessment 
dd/mm/yyyy 
 
Age at Assessment, years Weight, kg 
 
Height, cm BMI, kg/m2 
 
Mothers Height, cm 
Fathers Height, cm Mid Parental Height, cm Original Sex Assigned 




Male/ Female/ Both/ Not 
assigned/ Other 
Adolescent raised as 




Bone Age, Bone Mineral Density      
Bone Age Date 
dd/mm/yyyy 
Bone Age Result, years Bone Age Method 
TW20/ Radius-ulna-short bone/ 
Greulich & Pyle 
Bone Mineral Density 
Yes/ No/ Not known  
Bone Mineral Density Date 
dd/mm/yyyy 




Puberty      
Breast Stage 
1/ 2/ 3/ 4/ 5/ Not Known 
 
Genital Stage 
1/ 2/ 3/ 4/ 5/ Not Known 
Axillary Hair Stage 
1/ 2/ 3/ 4/ 5/ Not Known 
Pubic Hair Stage 
1/ 2/ 3/ 4/ 5/ Not Known 
Left Testicular Volume, ml Right Testicular Volume, ml 
Stretched Penile Length; cm 
 
Spontaneous Puberty 
Yes/ No/ Not known 
 
Pubertal Induction 
Yes/ No/ Not known 
Induction with Oestrogen 
Yes (Oral, Transdermal)/ No/ 
Not known 
 
Induction with Testosterone 
Yes (IM, Oral, Transdermal)/ 
No/ Not known 
 
Menarche  
Spontaneous/ Induced/ Not 
known 
Hirsutism 
Yes/ No/ Not known 
Gynaecomastia 
Yes/ No/ Not known 
 
    
Internal Phenotype      
Imaging Modality- Left Testis 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Imaging Modality- Right Testis 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Testis Morphology 
Absent/ Normal/ Small/ 
Abnormal 
Right Testis Morphology 
Absent/ Normal/ Small/ 
Abnormal 
Imaging Modality- Uterus 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Uterus Morphology 
Absent/ Normal/ Hypoplastic/ 
Abnormal 
 
Imaging Modality- Left Ovary 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Imaging Modality- Right Ovary 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Ovary Morphology 
Absent/ Streak/ Normal/ 
Polycystic 
 
Right Ovary Morphology 




Surgery      
Left Gonad Biopsy 
Yes/ No/ Not known 
 
Right Gonad Biopsy 
Yes/ No/ Not known 
 
Left Gonadectomy 
Yes/ No/ Not known 
 
Right Gonadectomy 




None/ clitoral surgery / 
vaginal surgery / labioscrotal 
surgery / hypospadias surgery 
/ urethral surgery other than 




Yes / No/ Not known 
 
Medical management of 
vaginal hypoplasia 
Dilation / Surgery / None 
 
Type of Vaginoplasty 
Intestinal / Peritoneal / 
Davydov / Vecchietti / Baloon 
/ Other  
 
Post Surgical Complications  
Yes/ No/ Not known; if yes, 
describe 
 
Gonadal Germ Cell Cancer 














Psychosocial, Gender Identity      
Change in Legal Sex 
Yes/ No/ Not known 
Psychosocial Support for Parents 
Yes/ No/ Not known 
 
Ongoing Psychosocial Support 
for Parents 
Yes/ No/ Not known 
 
Psychosocial Support Offered 
to Child 
Yes/ No/ Not known 
 
Ongoing Psychosocial 
Support for Child 




Yes/ No/ Not known 
 
Has Child Questioned Their 
Gender  
Yes/ No/ Not known 
 
Is Child Distressed About Gender 
Identity or Assignment 
Yes/ No/ Not known 
 
Physical or Mental Health 
Status Interferes with  
Daily Life Activities (education, 
work) 
Yes / Partially / No 
 
Physical or Mental Health 
Status Interferes with Social 
Activities (hobbies, friends, 
relations) 
Yes / Partially / No 
 
  
Sexual Health      
Menses 
Yes/ Primary amenorrhoea/ 
Secondary amenorrhoea 
 
Age at Menopause, years Fertility Desired 
Yes/ No/ Not known 
 
Tissue Storage 
Yes/ No/ Not known 
 
Sperm Assessment 
Yes/ No/ Not known 
 
Sperm count, per million/ml 
 x million per ml/ Normal/ 
Abnormal/ Not Reported  
Number of Offspring Assisted Conception 
Yes/ No/ Not known 
 
    
Medication      
Testosterone 




Yes (IM, Oral, Transdermal)/ No/ 
Not known 
Aromatase Inhibitor 
Yes/ No/ Not known 
GnRH analogues 
Yes/ No/ Not known 
Glucocorticoids 
Yes/ No/ Not known 
Fludrocortisone 
Yes/ No/ Not known 
Oestrogen 




Yes/ No/ Not known 
    
Lab Tests      
LH 
Low/ Normal/ High/ Not known 
 
FSH 
Low/ Normal/ High/ Not known 
 
AMH 
Low/ Normal/ High/ Not known 
 
Inhibin B 












Low/ Normal/ High/ Not known 
 
Dihydrotestosterone 
Low/ Normal/ High/ Not known 
 
Oestradiol 
Low/ Normal/ High/ Not known 
 
17-OHP 











Low/ Normal/ High/ Not known 
 
Total Testosterone 
Low/ Normal/ High/ Not known 
 
Dihydrotestosterone 




Adrenal Stimulation Test 
Specify protocol 
17-OHP 
Low/ Normal/ High/ Not known 
 
11-deoxycortisol 
Low/ Normal/ High/ Not known 
 
Pregnenolone 
Low/ Normal/ High/ Not 
known 
17-OH Pregnenolone 
Low/ Normal/ High/ Not 
known 
DHEA 
Low/ Normal/ High/ Not 
known 
*Associated conditions: CNS, Heart, Renal, Skeletal, Skin, ENT, Eyes, Blood and Lymp, Craniofacial, Adrenal, GI Tract, Haematological, Respiratory, SGA (Small for 
Gestational Age), Short stature, Non-defined syndrome, Other. ** Genital reconstructive surgery field may be repeated. 
 
Table 5: Adult assessment (once per interval: 18-25; 25-40; 40-60; 60-75 years) 
General      
Date of Assessment 
dd/mm/yyyy 
 
Age at Assessment, years Weight, kg 
 
Height, cm BMI, kg/m2 
 
Mothers Height, cm 
Fathers Height, cm Mid Parental Height, cm Original Sex Assigned 




Male/ Female/ Both/ Not 
assigned/ Other 
Adult raised as 




Bone Age, Bone Mineral Density      
Bone Age Date 
dd/mm/yyyy 
Bone Age Result, years Bone Age Method 
TW20/ Radius-ulna-short bone/ 
Greulich & Pyle 
Bone Mineral Density 
Yes/ No/ Not known  
Bone Mineral Density Date 
dd/mm/yyyy 




Puberty      
Breast Stage 
1/ 2/ 3/ 4/ 5/ Not Known 
 
Genital Stage 
1/ 2/ 3/ 4/ 5/ Not Known 
Axillary Hair Stage 
Yes/ No/ Not Known 
Pubic Hair Stage 
1/ 2/ 3/ 4/ 5/ 6/ Not Known 
Left Testicular Volume, ml Right Testicular Volume, ml 
Spontaneous Puberty 
Yes/ No/ Not known 
 
Pubertal Induction 
Yes/ No/ Not known 
Induction with Oestrogen 
Yes (Oral, Transdermal)/ No/ 
Not known 
 
Induction with Testosterone 
Yes (IM, Oral, Transdermal)/ 
No/ Not known 
 
Menarche  
Spontaneous/ Induced/ Not 
known 
Hirsutism 
Yes/ No/ Not known 
Gynaecomastia 
Yes/ No/ Not known 
 
     
Comorbidities      
Osteoporosis 
Yes/ No/ Not known 
 
Type II Diabetes 
Yes/ No/ Not known 
Chronic Kidney Disease 
Yes/ No/ Not known 
Chronic Liver Disease 
Yes/ No/ Not known 
Central Nervous System 
Yes/ No/ Not known 
 
Hypertension 
Yes/ No/ Not known 
Other 
Yes/ No/ Not known; if yes, 
describe 
     
Internal Phenotype      
Imaging Modality- Left Testis Imaging Modality- Right Testis Left Testis Morphology Right Testis Morphology Imaging Modality- Uterus Uterus Morphology 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Absent/ Normal/ Small/ 
Abnormal 
Absent/ Normal/ Small/ 
Abnormal 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Absent/ Normal/ Hypoplastic/ 
Abnormal 
 
Imaging Modality- Left Ovary 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Imaging Modality- Right Ovary 
US/ MRI/ Genitogram/ 
Laparoscopy/ Genitoscopy 
Left Ovary Morphology 
Absent/ Streak/ Normal/ 
Polycystic 
 
Right Ovary Morphology 




Surgery      
Left Gonad Biopsy 
Yes/ No/ Not known 
 
Right Gonad Biopsy 
Yes/ No/ Not known 
 
Left Gonadectomy 
Yes/ No/ Not known 
 
Right Gonadectomy 




None/ clitoral surgery / 
vaginal surgery / labioscrotal 
surgery / hypospadias surgery 
/ urethral surgery other than 
hypospadias / phalloplasty; 
age 
Vaginal Hypoplasia 
Yes / No/ Not known 
 
Medical management of 
vaginal hypoplasia 
Dilation / Surgery / None 
 
Type of Vaginoplasty 
Intestinal / Peritoneal / 
Davydov / Vecchietti / Baloon 
/ Other / Unknown 
 
Post Surgical Complications of 
Genital Surgery  
Yes/ No/ Not known; if yes, 
describe 
 
Gonadal Germ Cell Cancer 














None / breast 
reconstruction/augmentation
/ reduction/ mastectomy 
Post Surgical Complications 
of Breast Surgery  
Yes/ No/ Not known; if yes, 
describe 
 
Psychosocial, Gender Identity      
Change in Legal Sex 
Yes/ No/ Not known 
Psychosocial Support Offered 
Yes/ No/ Not known 
 
Ongoing Psychosocial Support 
Yes/ No/ Not known 
 
Full Information about 
Condition 
Yes/ No/ Not known 
 
Gender Role 
Female/ Male/ Both/ Neither/ 
Not known 
 
Physical or Mental Health 
Status Interferes with  
Daily Life Activities 
(education, work) 
Yes / Partially / No 
 
Physical or Mental Health 
Status Interferes with Social 
Activities (hobbies, friends, 
relations) 
Yes / Partially / No 
 
Sexual Health      
Menses 
Y/ Primary amenorrhoea/ 
Secondary amenorrhoea 
Age at Menopause, years Fertility Desired 
Yes/ No/ Not known 
 
Tissue Storage 
Yes/ No/ Not known 
 
Sperm Assessment 
Yes/ No/ Not known 
 
Sperm count, per million/ml 
 x million per ml/ Normal/ 
Abnormal/ Not Reported  
Number of Offspring Assisted Conception 
Yes/ No/ Not known 
 
    
Medication      
Testosterone 




Yes (IM, Oral, Transdermal)/ No/ 
Not known 
Aromatase Inhibitor 
Yes/ No/ Not known 
GnRH analogues 
Yes/ No/ Not known 
Glucocorticoids 
Yes/ No/ Not known 
Fludrocortisone 
Yes/ No/ Not known 
Oestrogen (E) 
Yes (IM, Oral, Transdermal)/ No/ 
Not known  
 
Progestin (P) 
Yes (Oral, Subcutaneous, IM, IUD) 
/ No/ Unknown 
Combined E/P (HRT/OC***) 
Yes (Oral, Transdermal, 
Vaginal)/ No/ Not known  
 
Other Drugs 
Yes/ No/ Not known 
  
Lab Tests      
LH 
Low/ Normal/ High/ Not known 
 
FSH 
Low/ Normal/ High/ Not known 
 
AMH 
Low/ Normal/ High/ Not known 
 
Inhibin B 












Low/ Normal/ High/ Not known 
 
Dihydrotestosterone 
Low/ Normal/ High/ Not known 
 
Oestradiol 
Low/ Normal/ High/ Not known 
 
17-OHP 











Low/ Normal/ High/ Not known 
 
Total Testosterone 
Low/ Normal/ High/ Not known 
 
Dihydrotestosterone 




Adrenal Stimulation Test 
Specify protocol 
17-OHP 
Low/ Normal/ High/ Not known 
 
11-deoxycortisol 
Low/ Normal/ High/ Not known 
 
Pregnenolone 
Low/ Normal/ High/ Not 
known 
17-OH Pregnenolone 
Low/ Normal/ High/ Not 
known 
DHEA 
Low/ Normal/ High/ Not 
known 
*Associated conditions: CNS, Heart, Renal, Skeletal, Skin, ENT, Eyes, Blood and Lymp, Craniofacial, Adrenal, GI Tract, Haematological, Respiratory, SGA (Small for 
Gestational Age), Short stature, Non-defined syndrome, Other. ** Genital reconstructive surgery field may be repeated. ***Hormonal replacement treatment/Oral 
contraceptives 
 
Supplementary Table 1: Tool for assessment of hypospadias (repair) 
Assessment prior to surgery 
External genitalia score 
(EGS), glans diameter, 
penile length, anogenital 
distance, penile deviation 
Assess androgen action in utero and objective description of 
hypospadias with a special interest on surgical items (severity of 
hypospadias, possible prognostic parameters) 
Intraoperative assessment 
Age at surgery  
Hormonal stimulation prior 
to surgery 
 
Type of surgery Surgical details (technique, staged repair) 
Postoperative assessment and follow-up (core set of outcome parameters) 
Date of follow-up Follow-up at crucial time-points (postoperative period, time of 
potty training, adolescence) 
Complications Surgical and other complications 
Repeat surgery When, why and what type of surgery 
Cosmesis Validated score (hypospadias objective penile evaluation score, 
HOPE score [1], modified) assessing surgical correctable items 
including meatal position, shape of meatus, shape of glans, shape of 
skin, cosmesis of scrotum, penile curvature and penile torsion 
Function Uroflow + ultrasound for residual volume 
Questionnaire for erectile dysfunction (International Index of 
Erectile Function 5, IIEF-5) 
Psychology Validated questionnaires for health related quality of life and sexual 
quality of life 
[1] van der Toorn F, de Jong TP, de Gier RP, Callewaert PR, van der Horst EH, Steffens MG, et al. Introducing the HOPE 
(Hypospadias Objective Penile Evaluation)-score: a validation study of an objective scoring system for evaluating cosmetic 
appearance in hypospadias patients. Journal of pediatric urology. 2013;9:1006-16. 
 
   Supplementary Table 2. Gynaecological assessment tool for longitudinal DSD care 
 
EXTERNAL GENITALIA 
 Pubic hair Normal scanty, hypertrophic 
 Labia Majora Normal asymmetric, hypertrophic, hypotrophic, absent 
 Labia Minora Normal asymmetric, hypertrophic, hypotrophic, absent 
 Clitoris (size mm)  hypertrophic, hypotrophic, 
 Ano – vulvar distance (from posterior labial commissure to the anus in mm): 
VAGINA 
 Lenght cm  scanty, hypertrophic 




self stimulation Normal absent sensitivity, low sensitivity, discomfort, pain 
partner stimulation Normal absent sensitivity, low sensitivity, discomfort, pain 
Vaginal 
sensitivity 
self stimulation Normal absent sensitivity, low sensitivity, discomfort, pain 
partner stimulation Normal absent sensitivity, low sensitivity, discomfort, pain 
Dispareunia No/Yes always, occasional, sporadic (pain intensity from 0 to 10) 
Bleeding Normal always, occasional, sporadic 
Discharge Normal always, occasional, sporadic 
AGE AT GENITAL SURGERY     
Date of surgery ddmmyyyy ddmmyyyy ddmmyyyy ddmmyyyy 
SURGERY DESCRIPTION     
Time from last surgery years/months 
JUDGEMENTS ON SURGERY 
Are you happy with the surgery performed on your genitalia? Yes/ No 
If you had surgery during infancy or before you could decide on your surgery, do you agree with your Yes/ No 
Do you think the age of the surgery you had was appropriate? (for every surgery done) Yes/ No 
Did the surgery met your objections? Yes/ No 
VAGINAL DILATION  
Previous use of vaginal dilators? No/Yes Age at first vaginal dilation treatment 
 Size of biggest dilator used (1 to 5) 
Currently using dilators? No/Yes Size of dilator in use (1 to 5) 
 
